Application of the Western-based adjuvant online model to Korean colon cancer patients; a single institution experience.
BACKGROUND
Adjuvant Online (AOL) is web-accessible risk-assessment model that predicts the mortality and the benefits of adjuvant therapy (http://www.newadjuvantonline.com). AOL has never been validated for Asian colon cancer patients.


METHODS
Using the Yonsei Tumor Registry database, patients who were treated within the Yonsei University Health System between 1990 and 2005 for T1-4, N0-2, and M0 colon cancer were included in the calculations for survival. Observed and predicted 5-year overall survival was compared for each patient.


RESULTS
The median age of the study population of 1431 patients was 60 years (range, 15-87 years), and the median follow-up duration was 7.9 years (range, 0.06-19.8 years). The predicted 5-year overall survival rate (77.7%) and observed survival (79.5%) was not statistically different (95% Confidential interval, 76.3-81.5) in all patients. Predicted outcomes were within 95% confidential interval of observed survival in both stage II and III disease, including most demographic and pathologic subgroups. Moreover, AOL more accurately predicted OS for patients with stage II than stage III.


CONCLUSIONS
AOL tended to offer reliable prediction for 5-year overall survival and could be used as a decision making tool for adjuvant treatment in Korean colon cancer patients whose prognosis is similar to other Asian patients.
Division of Medical Oncology, Department of Internal Medicine, Yonsei University College of Medicine, 50 Yonsei-ro, Seodaemun-go, Seoul, 120-752, Korea.
Minkyu
M
Jung
Geon Woo
GW
Kim
Inkyung
I
Jung
Joong Bae
JB
Ahn
Jae Kyung
JK
Roh
Sun Young
SY
Rha
Hyun Cheol
HC
Chung
Nam Kyu
NK
Kim
Tae Il
TI
Kim
Sang Joon
SJ
Shin
D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D017024:Chemotherapy, Adjuvant; D003110:Colonic Neoplasms / Q000188:drug therapy* / Q000401:mortality* / Q000473:pathology; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D053208:Kaplan-Meier Estimate; D007723:Korea; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D009862:Online Systems; D018570:Risk Assessment; D016896:Treatment Outcome; D055815:Young Adult
D000970:Antineoplastic Agents